SKIN The Journal of Cutaneous Medicine

Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Andrew Blauvelt, Anderas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong , Lynda Spelman, Hidehisa Saeki, Charles Lynde, Pedro Herranz, Sebastien Barbarot, Eric Simpson

Page s57

Poster PDF

Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Regional Differences in Baseline Disease Characteristics and Prior Treatment in the ECZTRA 1 and ECZTRA 2 Trials

Eric Simpson, Thomas Werfel, Thomas Bieber, Louise Steffensen, Alexandra Kuznetsova, Marie ?sterdal, Hidehisa Saeki

Page s101

Poster PDF

Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)

Eric Simpson, Andrew Blauvelt, Emma Guttman-Yassky, Margitta Worm, Charles Lynde, Hidehisa Saeki, Yves Poulin, Andreas Wollenberg

Page s96

Poster PDF

Search

Search Results

Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Regional Differences in Baseline Disease Characteristics and Prior Treatment in the ECZTRA 1 and ECZTRA 2 Trials

Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)